2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - La Nouvelle C
Technology and Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

643 Immune effector cell-associated enterocolitis after ciltacabtagene autoleucel: Incidence, features, and outcomes from the US multiple myeloma immunotherapy consortium

Lekha Mikkilineni, MD, MA, Alexandria Jensen, Phd2, Anupama Kumar3, Gliceida Galarza Fortuna, MD4, Hitomi Hosoya, MD,PhD5, Alicia Richards, PHD, MS6, Andrew J. Portuguese, MD7, Caleb Hwang8, Lauren C Peres, PhD, MPH9, Saurabh Zanwar, MBBS, MD10, Danai Dima, MD11, Mahmoud R. Gaballa, MD12, Omar Alexis Castaneda Puglianini, MD13, Ariel F. Grajales-Cruz, MD14, Ricardo Daniel Parrondo, MD15, Aimaz Afrough, MD16, Shonali Midha, MD17, Christopher Ferreri, MD18, Cindy Varga, MD19, Francesca Cottini, MD20, Melinda Tan21, Christopher Cahoon, PharmD22, James A Davis, PharmD, BCOP23, Susan Bal, MD24, Sneha Purvey, MD25, Karen Sweiss, PharmD26, Asya Varshavsky, MD27, Lorenzo Gensini, MD28, Sharlene Dong, MD, MS29, Jennifer Ann Kanakry, MD30, Megan M Herr, PhD31, Chenyu Lin, MD32, Omar Nadeem, MD33, Binoy Yohannan, MD34, Timothy O'Brien, MD35, Noa Biran, MD36, Marcus Geer, MD37, Rahul Banerjee, MD, FACP38, Ran Reshef, MD39, Ashley Rosko, MD40, Ciara Louise L Freeman, MD, PhD41, Samer Al Hadidi, MD42, Kenneth H. Shain, MD, PhD43, Nisha Joseph, MD44, Saurabh Chhabra, MD, MBBS45, Larry D Anderson Jr, MD, PhD46, Oren Pasvolsky, MD47, Alissa Visram, MD, MPH48, Hira Mian, MD49, Frederick L. Locke, MD50, Luciano J. Costa, MD, PhD51, David Y. Oh, MD, PhD52, Maximilian Merz, MD53, Mark P Hamilton, MD54, Jeffrey Lee Wolf, MD55, Krina Patel Jr, MD, MSc56, Surbhi Sidana, MD57, Yi Lin Jr, MD, PhD58, Doris K. Hansen, MD59, Doug W. Sborov, MD, MS60
1 Stanford University School of Medicine, PALO ALTO, California, United States
2 Stanford University School of Medicine, PALO ALTO, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 Huntsman Cancer Institute, Salt Lake City, United States
5 Cedars-Sinai Medical Center, Los Angeles, California, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 Fred Hutchinson Cancer Center, Seattle, United States
8 University of California San Francisco, San Francisco, California, United States
9 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
10 Mayo Clinic Comprehensive Cancer Center, Rochester, United States
11 Fred Hutchinson Cancer Center, Seattle, United States
13 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
15 Mayo Clinic, Jacksonville, Florida, United States
16 Simmons Comprehensive Cancer Center, Dallas, Texas, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
19 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
20 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Ohio, California, United States
21 Mayo Clinic Comprehensive Cancer Center, Rochester, United States
22 Huntsman Cancer Institute, Salt Lake City, United States
23 Medical University of South Carolina, Charleston, California, United States
24 University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, United States
25 VCU Health, University of Illinois Chicago, Virginia, United States
26 University of Illinois Chicago, Chicago, Illinois, United States
27 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
28 The University of Texas MD Anderson Cancer Center, Houston, California, United States
29 The University of Texas MD Anderson Cancer Center, Houston, California, United States
30 MedStar Georgetown University Hospital, Washington D.C, United States
31 Roswell Park Comprehensive Cancer Center, Buffalo, United States
32 Duke Cancer Institute, Durham, United States
33 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
34 University of Minnesota, Minneapolis, United States
35 University Hospitals Seidman Cancer Center, Cleveland, OH, United States
36 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, United States
37 University of Michigan Rogel Cancer Center, Ann Arbor, United States
38 Fred Hutchinson Cancer Center, Seattle, United States
39 Herbert Irving Comprehensive Cancer Center, New York City, United States
40 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Ohio, California, United States, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Ohio, California, United States
41 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
42 Simmons Comprehensive Cancer Center, Dallas, Texas, United States
43 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
44 Emory University School of Medicine, Winship Cancer Institute, Atlanta, United States
45 Mayo Clinic Comprehensive Cancer Center, Pheonix, United States
46 Simmons Comprehensive Cancer Center, Dallas, Texas, United States
47 The University of Texas MD Anderson Cancer Center, Houston, California, United States
48 McMaster University, Hamilton, Canada
49 McMaster University, Hamilton, Canada
50 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
51 University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, United States
52 University of California San Francisco, San Francisco, California, United States
53 Memorial Sloan Kettering Cancer Center, New York City, United States, University of Leipzig, Leipzig, Germany
54 The University of Texas MD Anderson Cancer Center, Houston, California, United States
55 University of California San Francisco, San Francisco, California, United States
56 The University of Texas MD Anderson Cancer Center, Houston, California, United States
57 Stanford University School of Medicine, PALO ALTO, California, United States
58 Mayo Clinic Comprehensive Cancer Center, Rochester, United States
59 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
60 Huntsman Cancer Institute, Salt Lake City, United States

Introduction: IEC-enterocolitis (IEC-EC) is a rare but serious toxicity described after ciltacabtagene autoleucel (cilta-cel) therapy for multiple myeloma (MM). Prior incidence estimates were derived from small case series, and features associated with IEC-EC remain poorly characterized. We evaluated the incidence, clinical features, and outcomes of IEC-EC following cilta-cel. 

Methods: We retrospectively analyzed patients (pts) receiving commercial cilta-cel across the U.S. Multiple Myeloma Immunotherapy Consortium. Pts with IEC-EC were compared to those without across baseline demographics, disease and cytogenetic risk, prior therapies, bridging therapy, and pre-infusion laboratory parameters. Chi-square/Fisher's exact and t-test/Mann-Whitney U tests were used as appropriate. Best response, PFS, OS, and non-relapse mortality (NRM) were assessed.

Results: Among 1,793 cilta-cel-treated pts across the 23 consortium sites, 55 had provider-adjudicated IEC-EC, for an overall cumulative incidence (1-yr Aalen-Johansen estimate for competing risk of death) of 3.0%. Of the 55 cases, 29 had previously been reported focusing on pathological features (Mikkilineni et al., in press) and 26 were newly captured, including from 9 previously unrepresented sites. Aalen-Johansen adjusted cumulative incidence rose across successive infusion-year cohorts (1.8% [n=2 new cases] in 2022, 2.0% [n=7] in 2023, 2.7% [n=19] in 2024, 3.9% [n=27] in 2025), likely reflecting increasing recognition of IEC-EC. Median time to IEC-EC onset was 96 days (IQR 57.5-126.75).

IEC-EC (n=55) and non–IEC-EC (n=1,738) pts shared baseline characteristics, with older age the only significant difference (mean 67.7 vs 64.4 years; p<0.001). No associations were observed between IEC-EC and MM disease risk, including high-risk cytogenetics (40.0% vs 37.2%; p=0.46), extramedullary disease (18.2% vs 17.1%; p=0.86), triple-refractory status (56.4% vs 59.0%; p=0.58), number of prior lines of therapy (median 4 vs 4; p=0.70), functional high-risk disease (p=0.99), prior BCMA (p=0.82)/GPRC5D (p=0.30) directed therapy, or pre-LD CAR-HEMATOTOX risk (high-risk 30.9% vs 29.9%; p=0.88). Pre-infusion laboratory differences were limited to lower apheresis IgA, which persisted after excluding IgA-subtype myeloma (p=0.01), and lower pre-lymphodepletion hemoglobin (p=0.01).. Bridging strategy (no bridging, alkylator-containing, or other bridging) did not differ by IEC-EC status (p=0.20); alkylator-containing bridging was numerically more common in IEC-EC pts (34.5% vs 24.7%).

CRS (85.5% vs 74.2%; OR 2.15, 95% CI 0.96-5.69; p=0.08) and IEC-HS (9.1% vs 4.7%; OR 1.92, 95% CI 0.58-4.99; p=0.20) were not significantly associated with IEC-EC; ICANS did not differ (18.2% vs 15.5%; OR 1.23, 95% CI 0.54-2.52; p=0.70). Non-ICANS neurological toxicities (NINTs) were significantly more common in IEC-EC pts, including Parkinsonian neurotoxicity (12.7% vs 2.8%; OR 4.83, 95% CI 2.20-11.51; p=0.0015) and cranial nerve palsy (21.8% vs 9.6%; OR 2.28, 95% CI 1.16-4.94; p=0.011). Infections occurred in 37/55 (67%) pts; most were bacterial and 38 of 62 infections (61%) were investigator-graded severe.

Among the 55 IEC-EC pts, 31 (56%) died, including 29 without MM progression. Deaths were largely due to complications of IEC-EC, infection, or treatment-related toxicity (12-month NRM 51%, 95% CI 36-64%, with relapse as a competing risk); only 2 died of MM progression, both with unresolved colitis.

Conclusion: In the largest cohort reported to date, IEC-EC incidence after cilta-cel was 3.0% and rose across successive infusion-year cohorts. Beyond older age, affected patients were largely indistinguishable from unaffected patients across standard demographic, disease, and cytogenetic risk factors, indicating that established myeloma risk-stratification tools do not predict IEC-EC risk. IEC-EC was frequently accompanied by non-ICANS neurotoxicities including parkinsonism and cranial nerve palsy, and was associated with substantial NRM despite control of the underlying myeloma. Because no baseline clinical predictors of IEC-EC were identified, these findings highlight an unmet need for prospective studies to define its biological drivers, enable earlier recognition, and guide effective treatment strategies.

Lekha Mikkilineni, MD, MA: Legend Biotech - Consultancy (Includes expert testimony); Jansen - Consultancy (Includes expert testimony); Cartesian Therapeutics - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony)